158 related articles for article (PubMed ID: 25410684)
1. Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer.
Tan HJ; Meyer AM; Kuo TM; Smith AB; Wheeler SB; Carpenter WR; Nielsen ME
Cancer; 2015 Mar; 121(6):836-43. PubMed ID: 25410684
[TBL] [Abstract][Full Text] [Related]
2. Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community.
Penn DC; Chang Y; Meyer AM; DeFilippo Mack C; Sanoff HK; Stitzenberg KB; Carpenter WR
Cancer; 2015 Jan; 121(1):93-101. PubMed ID: 25209056
[TBL] [Abstract][Full Text] [Related]
3. Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.
Carpenter WR; Meyer AM; Wu Y; Qaqish B; Sanoff HK; Goldberg RM; Weiner BJ
Med Care; 2012 Aug; 50(8):737-48. PubMed ID: 22437624
[TBL] [Abstract][Full Text] [Related]
4. Diffusion of surgical innovation among patients with kidney cancer.
Miller DC; Saigal CS; Banerjee M; Hanley J; Litwin MS;
Cancer; 2008 Apr; 112(8):1708-17. PubMed ID: 18330868
[TBL] [Abstract][Full Text] [Related]
5. Differential receipt of sentinel lymph node biopsy within practice-based research networks.
Meyer AM; Reeder-Hayes KE; Liu H; Wheeler SB; Penn D; Weiner BJ; Carpenter WR
Med Care; 2013 Sep; 51(9):812-8. PubMed ID: 23942221
[TBL] [Abstract][Full Text] [Related]
6. Logic regression for provider effects on kidney cancer treatment delivery.
Banerjee M; Filson C; Xia R; Miller DC
Comput Math Methods Med; 2014; 2014():316935. PubMed ID: 24795774
[TBL] [Abstract][Full Text] [Related]
7. The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation.
Carpenter WR; Reeder-Hayes K; Bainbridge J; Meyer AM; Amos KD; Weiner BJ; Godley PA
Med Care; 2011 Feb; 49(2):172-9. PubMed ID: 21206296
[TBL] [Abstract][Full Text] [Related]
8. Health status and use of partial nephrectomy in older adults with early-stage kidney cancer.
Tan HJ; Daskivich TJ; Shirk JD; Filson CP; Litwin MS; Hu JC
Urol Oncol; 2017 Apr; 35(4):153.e7-153.e14. PubMed ID: 27955941
[TBL] [Abstract][Full Text] [Related]
9. Why providers participate in clinical trials: considering the National Cancer Institute's Community Clinical Oncology Program.
McAlearney AS; Song PH; Reiter KL
Contemp Clin Trials; 2012 Nov; 33(6):1143-9. PubMed ID: 22925970
[TBL] [Abstract][Full Text] [Related]
10. Provider-based research networks demonstrate greater hospice use for minority patients with lung cancer.
Penn DC; Stitzenberg KB; Cobran EK; Godley PA
J Oncol Pract; 2014 Jul; 10(4):e182-90. PubMed ID: 24781367
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer.
Tan HJ; Norton EC; Ye Z; Hafez KS; Gore JL; Miller DC
JAMA; 2012 Apr; 307(15):1629-35. PubMed ID: 22511691
[TBL] [Abstract][Full Text] [Related]
12. Implementing community-based provider participation in research: an empirical study.
Teal R; Bergmire DM; Johnston M; Weiner BJ
Implement Sci; 2012 May; 7():41. PubMed ID: 22568935
[TBL] [Abstract][Full Text] [Related]
13. Hospital characteristics and use of innovative surgical therapies among patients with kidney cancer.
Miller DC; Daignault S; Wolf JS; Hafez KS; Kieran K; Dunn RL; Hollenbeck BK
Med Care; 2008 Apr; 46(4):372-9. PubMed ID: 18362816
[TBL] [Abstract][Full Text] [Related]
14. Population level assessment of hospital based outcomes following laparoscopic versus open partial nephrectomy during the adoption of minimally invasive surgery.
Tan HJ; Wolf JS; Ye Z; Hafez KS; Miller DC
J Urol; 2014 May; 191(5):1231-7. PubMed ID: 24211600
[TBL] [Abstract][Full Text] [Related]
15. Patient safety and the diffusion of surgical innovations: a national analysis of laparoscopic partial nephrectomy.
Parsons JK; Palazzi K; Chang D; Stroup SP
Surg Endosc; 2013 May; 27(5):1674-80. PubMed ID: 23239306
[TBL] [Abstract][Full Text] [Related]
16. A method for analyzing the business case for provider participation in the National Cancer Institute's Community Clinical Oncology Program and similar federally funded, provider-based research networks.
Reiter KL; Song PH; Minasian L; Good M; Weiner BJ; McAlearney AS
Cancer; 2012 Sep; 118(17):4253-61. PubMed ID: 22213241
[TBL] [Abstract][Full Text] [Related]
17. Toward greater adoption of minimally invasive and nephron-sparing surgical techniques for renal cell cancer in the United States.
Banegas MP; Harlan LC; Mann B; Yabroff KR
Urol Oncol; 2016 Oct; 34(10):433.e9-433.e17. PubMed ID: 27321355
[TBL] [Abstract][Full Text] [Related]
18. Organizational and physician factors associated with patient enrollment in cancer clinical trials.
Jacobs SR; Weiner BJ; Reeve BB; Weinberger M; Minasian LM; Good MJ
Clin Trials; 2014 Oct; 11(5):565-75. PubMed ID: 24902923
[TBL] [Abstract][Full Text] [Related]
19. Renal and cardiovascular morbidity after partial or radical nephrectomy.
Miller DC; Schonlau M; Litwin MS; Lai J; Saigal CS;
Cancer; 2008 Feb; 112(3):511-20. PubMed ID: 18072263
[TBL] [Abstract][Full Text] [Related]
20. Surgeon characteristics and long-term trends in the adoption of laparoscopic radical nephrectomy.
Filson CP; Banerjee M; Wolf JS; Ye Z; Wei JT; Miller DC
J Urol; 2011 Jun; 185(6):2072-7. PubMed ID: 21496845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
